A Phase 2 interventional study of LDV/SOF and RBV in Hepatitis C Virus Infection, sponsored by Gilead Sciences. Completed at 31 sites in 4 countries. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-03-02.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 174 studies testing ribavirin in Hepatitis C — none open to participants now, 1 under way, none of them phase 3. Ribavirin · Hepatitis C.
Among the 174 studies testing ribavirin in Hepatitis C, this one is the 37th largest by enrollment, is one of 17 that started in 2014, is one of 47 in phase 2, and was the 135th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 174 studies testing ribavirin in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →
Ribavirin: first FDA approval 1985 (VIRAZOLE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 3 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
174 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 61 · Phase 3 64 · Phase 4 44
First in 1997; this study’s year is marked. 17 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 226 is above the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 78 across the 174 interventional studies. Of the 158 that completed or were terminated, 79 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 174 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
110 studies in Hepatitis C by Gilead Sciences: none open now, none under way, none of them phase 3. Of 109 finished, 79 (72%) have results posted.
Among the 110 studies in Hepatitis C by Gilead Sciences, this one is the 27th largest by enrollment of the 97 interventional ones that give a count, is one of 15 that started in 2014, is one of 47 in phase 2, and was the 61st registered.
Gilead Sciences’s Hepatitis C studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 174 studies testing ribavirin in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 110 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the PK Lead-in Phase of the study is to evaluate the steady state pharmacokinetics (PK) and confirm the dose of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) in hepatitis C virus (HCV)-infected pediatric participants. The PK Lead-in Phase will also evaluate the safety, tolerability, and antiviral activity of 10 days of dosing of LDV/SOF FDC in HCV-infected pediatric participants.
The Treatment Phase will be initiated by age cohort after confirmation of age-appropriate LDV/SOF FDC dosage levels. Participants from the PK Lead-in Phase will immediately rollover into the Treatment Phase with no interruption of study drug administration. The primary objective of the Treatment Phase is to evaluate the antiviral efficacy, safety, and tolerability of LDV/SOF FDC +/- ribavirin (RBV) for 12 or 24 weeks in pediatric participants with HCV.
During screening, participants will receive placebo to match LDV/SOF FDC to assess ability to swallow tablets.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants between 12 to \< 18 years of age weighing ≥ 45 kg will receive LDV/SOF FDC (90/400 mg tablet or 4 x 22.5 mg/100 mg tablets or 8 x 11.25/50 mg granules based on swallowability assessment during screening). Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment. United Kingdom: * HCV genotypes (GT) 1, 4, 5, or 6 treatment-naive (TN) with or without cirrhosis = LDV/SOF 12 weeks * HCV GT 1, 4, 5, or 6 treatment-experienced (TE) without cirrhosis = LDV/SOF 12 weeks * HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks * HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks United States/Australia/New Zealand: * HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks * HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks * HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks * HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks
Drug: LDV/SOF · Drug: RBV
Participants between 6 to \< 12 years of age weighing ≥ 17 kg and \< 45 kg will receive LDV/SOF FDC (45/200 mg as 2 x 22.5/100 mg tablets or 4 x 11.25/50 mg granules based on swallowability assessment during screening). Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment. United Kingdom: * HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks * HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks * HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks * HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks United States/Australia/New Zealand: * HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks * HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks * HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks * HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks
Drug: LDV/SOF · Drug: RBV
Participants between 3 to \< 6 years of age weighing ≥ 17 kg will receive LDV/SOF FDC (45/200 mg granules as 4 x 11.25/50 mg packets) and participants weighing \< 17 kg will receive LDV/SOF FDC (33.75/150 mg oral granules as 3 x 11.25/50 mg packets). Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment. United Kingdom: * HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks * HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks * HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks * HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks United States/Australia/New Zealand: * HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks * HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks * HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks * HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks
Drug: LDV/SOF · Drug: RBV
LDV/SOF FDC administered orally once daily
Also known as: Harvoni®, GS-5885/GS-7977
Ribavirin (RBV) oral solution or capsules will be administered orally in a divided daily dose based on weight
Also known as: REBETOL®
For Participants in the PK Lead-in Phase, Pharmacokinetic (PK) Parameter: AUCtau of GS-331007 (Metabolite of SOF), LDV, and SOF
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
Time frame: Cohorts 1 and 2 (6 to < 18 years of age): predose, 0.5, 1, 2, 3, 4, 5, 8, and 12 hours postdose on Day 10; Cohort 3 (3 to < 6 years of age): predose, 0.5, 2, 4, 8, and 12 hours postdose on Day 10
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase or the Treatment Phase
Time frame: Up to 24 weeks
For Participants in the PK Lead-in Phase, Change From Baseline in HCV RNA
Time frame: Baseline; Weeks 1, 2, 4, 8, and 12
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase
Time frame: Up to Day 10
For the Treatment Phase, Percentage of Participants With Sustained Virologic Response (SVR) at 4 Weeks After Discontinuation of Therapy (SVR4)
SVR4 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 4 weeks after stopping study treatment.
Time frame: Posttreatment Week 4
For the Treatment Phase, Percentage of Participants With SVR at 12 Weeks After Discontinuation of Therapy (SVR12)
SVR12 was defined as HCV RNA \< LLOQ at 12 weeks after stopping study treatment.
Time frame: Posttreatment Week 12
For the Treatment Phase, Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)
SVR24 was defined as HCV RNA \< LLOQ at 24 weeks after stopping study treatment.
Time frame: Posttreatment Week 24
For the Treatment Phase, Percentage of Participants Experiencing Viral Breakthrough
Viral breakthrough was defined as having confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment.
Time frame: Up to 24 weeks
For the Treatment Phase, Percentage of Participants Experiencing Viral Relapse
Viral relapse was defined as having confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit.
Time frame: Up to Posttreatment Week 24
For the Treatment Phase, Change From Baseline in HCV RNA
Time frame: Baseline; Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only)
For the Treatment Phase, Percentage of Participants With HCV RNA < LLOQ While On Treatment
Time frame: Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only)
For the Treatment Phase, Percentage of Participants With Alanine Aminotransferase (ALT) Normalization
ALT normalization was defined as ALT \> the upper limit of normal (ULN) at baseline and ALT ≤ ULN at each visit.
Time frame: Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only), and Posttreatment Week 4
For the Treatment Phase, Change From Baseline in Height
Time frame: Baseline; Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only), and Posttreatment Weeks 4, 12, and 24
For the Treatment Phase, Change From Baseline in Weight
Time frame: Baseline; Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only), and Posttreatment Weeks 4, 12, and 24
For the Treatment Phase, Number of Male Participants With a Change From Baseline in Tanner Stage for Pubic Hair
Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.
Time frame: Baseline; End of Treatment (either Week 12 or 24), Posttreatment Week 12, and Posttreatment Week 24
For the Treatment Phase, Number of Male Participants With a Change From Baseline in Tanner Stage for Genitalia Development
Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.
Time frame: Baseline; End of Treatment (either Week 12 or 24), Posttreatment Week 12, and Posttreatment Week 24
For the Treatment Phase, Number of Female Participants With a Change From Baseline in Tanner Stage for Pubic Hair
Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.
Time frame: Baseline; End of Treatment (either Week 12 or 24), Posttreatment Week 12, and Posttreatment Week 24
For the Treatment Phase, Number of Female Participants With a Change From Baseline in Tanner Stage for Breast Development
Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.
Time frame: Baseline; End of Treatment (either Week 12 or 24), Posttreatment Week 12, and Posttreatment Week 24
Acceptability of LDV/SOF Tablets as Measured by the Percentage of Participants Able/Unable to Swallow Placebo Tablet at Day 1
Participants who were able/unable to swallow placebo tablets were assessed. Participants 12 to \< 18 years old were first asked to perform the swallowability assessment using the 90/400 mg placebo tablet. If they were unable to swallow this, they were then asked to perform the swallowability assessment with 22.5/100 mg placebo tablets. Participants 6 to \< 12 years old were to be assessed with the 22.5/100 mg placebo tablets. However, 8 participants were mistakenly assessed using the 90/400 mg placebo tablet.
Time frame: Day 1
Acceptability of LDV/SOF Granules as Measured by Palatability at Day 1
Participants who were dosed with granules were asked if they tasted the study drug. If they tasted it, then they were asked to provide a number from 0 to 100 to rate the taste of the study drug, with higher scores indicating better taste. Data was then summarized as percentage of participants choosing the following palatability categories: 1) Did not taste the study drug, 2) Tasted drug with score \> 60 to 100, 3) Tasted drug with score 40 to 60, and 4) Tasted drug with score of 0 to \< 40.
Time frame: Day 1
Participants were enrolled at study sites in the United States, United Kingdom, Australia, and New Zealand. The first participant was screened on 05 November 2014. The last study visit occurred on 24 August 2018.
| Milestone | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 24 Weeks | 6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks |
|---|---|---|---|---|---|
| Started | 10 | 12 | 0 | 0 | 17 |
| Completed | 10 | 12 | 0 | 0 | 17 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 24 Weeks | 6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks |
|---|---|---|---|---|---|
| Started | 100 | 89 | 1 | 2 | 34 |
| Completed | 96 | 89 | 1 | 2 | 34 |
| Not completed | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 4 | 0 | 0 | 0 | 0 |
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
| h*ng/mL | PK Lead-in: 12 to < 18 Years Old - LDV/SOF 12 Weeks | PK Lead-in: 6 to < 12 Years Old - LDV/SOF 12 Weeks | PK Lead-in: 3 to < 6 Years Old - LDV/SOF 12 Weeks |
|---|---|---|---|
| GS-331007 (metabolite of SOF) | 12682.5 ± 1732.66 | 8210.3 ± 2542.42 | 11688.9 ± 3400.79 |
| LDV | 10202.4 ± 5196.49 | 7288.3 ± 4547.33 | 9316.3 ± 3280.51 |
| SOF | 2175.7 ± 578.92 | 1754.4 ± 419.18 | 2495.2 ± 412.64 |
| percentage of participants | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 24 Weeks | 6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks |
|---|---|---|---|---|---|
| Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase or the Treatment Phase | 0 | 0 | 0 | 0 | 2.9 |
| log10 IU/mL | PK Lead-in: 12 to < 18 Years Old - LDV/SOF 12 Weeks | PK Lead-in: 6 to < 12 Years Old - LDV/SOF 12 Weeks | PK Lead-in: 3 to < 6 Years Old - LDV/SOF 12 Weeks |
|---|---|---|---|
| Change at Week 1 | -4.34 ± 0.621 | -4.29 ± 0.518 | -4.32 ± 0.616 |
| Change at Week 2 | -4.71 ± 0.651 | -4.55 ± 0.636 | -4.87 ± 0.724 |
| Change at Week 4 | -4.73 ± 0.667 | -4.75 ± 0.702 | -4.92 ± 0.715 |
| Change at Week 8 | -4.73 ± 0.667 | -4.76 ± 0.710 | -4.92 ± 0.715 |
| Change at Week 12 | -4.73 ± 0.667 | -4.76 ± 0.710 | -4.92 ± 0.715 |
| percentage of participants | PK Lead-in: 12 to < 18 Years Old - LDV/SOF 12 Weeks | PK Lead-in: 6 to < 12 Years Old - LDV/SOF 12 Weeks | PK Lead-in: 3 to < 6 Years Old - LDV/SOF 12 Weeks |
|---|---|---|---|
| Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase | 0 | 0 | 5.9 |
SVR4 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 4 weeks after stopping study treatment.
| percentage of participants | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 24 Weeks | 6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks |
|---|---|---|---|---|---|
| For the Treatment Phase, Percentage of Participants With Sustained Virologic Response (SVR) at 4 Weeks After Discontinuation of Therapy (SVR4) | 98.0 (93.0 to 99.8) | 98.9 (93.9 to 100.0) | 100.0 (2.5 to 100.0) | 100.0 (15.8 to 100.0) | 97.1 (84.7 to 99.9) |
SVR12 was defined as HCV RNA \< LLOQ at 12 weeks after stopping study treatment.
| percentage of participants | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 24 Weeks | 6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks |
|---|---|---|---|---|---|
| For the Treatment Phase, Percentage of Participants With SVR at 12 Weeks After Discontinuation of Therapy (SVR12) | 98.0 (93.0 to 99.8) | 98.9 (93.9 to 100.0) | 100.0 (2.5 to 100.0) | 100.0 (15.8 to 100.0) | 97.1 (84.7 to 99.9) |
SVR24 was defined as HCV RNA \< LLOQ at 24 weeks after stopping study treatment.
| percentage of participants | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 24 Weeks | 6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks |
|---|---|---|---|---|---|
| For the Treatment Phase, Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24) | 98.0 (93.0 to 99.8) | 98.9 (93.9 to 100.0) | 100.0 (2.5 to 100.0) | 100.0 (15.8 to 100.0) | 97.1 (84.7 to 99.9) |
Viral breakthrough was defined as having confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment.
| percentage of participants | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 24 Weeks | 6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks |
|---|---|---|---|---|---|
| For the Treatment Phase, Percentage of Participants Experiencing Viral Breakthrough | 0 | 0 | 0 | 0 | 0 |
Viral relapse was defined as having confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit.
| percentage of participants | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 24 Weeks | 6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks |
|---|---|---|---|---|---|
| For the Treatment Phase, Percentage of Participants Experiencing Viral Relapse | 0 | 1.1 | 0 | 0 | 0 |
| log10 IU/mL | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 24 Weeks | 6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks |
|---|---|---|---|---|---|
| Change at Week 1 | -4.34 ± 0.634 | -4.27 ± 0.592 | -4.30 ± NA | -4.54 ± 0.308 | -4.25 ± 0.505 |
| Change at Week 2 | -4.74 ± 0.585 | -4.73 ± 0.544 | -5.09 ± NA | -4.54 ± 0.308 | -4.80 ± 0.628 |
| Change at Week 4 | -4.84 ± 0.557 | -4.87 ± 0.592 | -5.09 ± NA | -4.54 ± 0.308 | -4.85 ± 0.628 |
| Change at Week 8 | -4.85 ± 0.556 | -4.89 ± 0.597 | -5.09 ± NA | -4.54 ± 0.308 | -4.86 ± 0.633 |
| Change at Week 12 | -4.85 ± 0.556 | -4.89 ± 0.597 | -5.09 ± NA | -4.54 ± 0.308 | -4.86 ± 0.633 |
| Change at Week 16 | — | — | -5.09 ± NA | -4.54 ± 0.308 | — |
| Change at Week 20 | — | — | -5.09 ± NA | -4.54 ± 0.308 | — |
| Change at Week 24 | — | — | -5.09 ± NA | -4.54 ± 0.308 | — |
| percentage of participants | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 24 Weeks | 6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks |
|---|---|---|---|---|---|
| Week 1 | 40.0 (30.3 to 50.3) | 30.3 (21.0 to 41.0) | 0 (0.0 to 97.5) | 100.0 (15.8 to 100.0) | 29.4 (15.1 to 47.5) |
| Week 2 | 75.0 (65.3 to 83.1) | 71.9 (61.4 to 80.9) | 100.0 (2.5 to 100.0) | 100.0 (15.8 to 100.0) | 78.8 (61.1 to 91.0) |
| Week 4 | 97.0 (91.5 to 99.4) | 96.6 (90.5 to 99.3) | 100.0 (2.5 to 100.0) | 100.0 (15.8 to 100.0) | 97.0 (84.2 to 99.9) |
| Week 8 | 100.0 (96.3 to 100.0) | 100.0 (95.9 to 100.0) | 100.0 (2.5 to 100.0) | 100.0 (15.8 to 100.0) | 100.0 (89.4 to 100.0) |
| Week 12 | 100.0 (96.3 to 100.0) | 100.0 (95.9 to 100.0) | 100.0 (2.5 to 100.0) | 100.0 (15.8 to 100.0) | 100.0 (89.4 to 100.0) |
| Week 16 | — | — | 100.0 (2.5 to 100.0) | 100.0 (15.8 to 100.0) | — |
| Week 20 | — | — | 100.0 (2.5 to 100.0) | 100.0 (15.8 to 100.0) | — |
| Week 24 | — | — | 100.0 (2.5 to 100.0) | 100.0 (15.8 to 100.0) | — |
ALT normalization was defined as ALT \> the upper limit of normal (ULN) at baseline and ALT ≤ ULN at each visit.
| percentage of participants | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 24 Weeks | 6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks |
|---|---|---|---|---|---|
| Week 1 | 72.3 | 75.7 | 0 | 50.0 | 63.0 |
| Week 2 | 89.8 | 84.8 | 0 | 50.0 | 84.0 |
| Week 4 | 93.8 | 93.1 | 0 | 100.0 | 96.0 |
| Week 8 | 91.3 | 90.1 | 0 | 100.0 | 92.0 |
| Week 12 | 93.3 | 95.5 | 100.0 | 100.0 | 91.7 |
| Week 16 | — | — | 100.0 | 100.0 | — |
| Week 20 | — | — | 100.0 | 100.0 | — |
| Week 24 | — | — | 100.0 | 100.0 | — |
| Posttreatment Week 4 | 90.2 | 98.4 | — | 100.0 | 91.3 |
| centimeters | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 24 Weeks | 6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks |
|---|---|---|---|---|---|
| Change at Week 1 | 0.1 ± 0.68 | 0.1 ± 0.83 | 0.3 ± NA | 0.7 ± 1.13 | 0.2 ± 1.24 |
| Change at Week 2 | 0.0 ± 0.70 | 0.3 ± 0.73 | 0.5 ± NA | 0.5 ± 0.85 | 0.3 ± 0.72 |
| Change at Week 4 | 0.1 ± 0.84 | 0.5 ± 0.79 | 1.2 ± NA | 0.6 ± 0.92 | 0.7 ± 0.79 |
| Change at Week 8 | 0.4 ± 1.04 | 0.8 ± 0.79 | 1.3 ± NA | 0.8 ± 0.92 | 1.0 ± 0.82 |
| Change at Week 12 | 0.5 ± 1.10 | 1.3 ± 0.83 | 2.1 ± NA | 1.1 ± 1.41 | 1.6 ± 0.98 |
| Change at Week 16 | — | — | 3.2 ± NA | 1.4 ± 1.06 | — |
| Change at Week 20 | — | — | 4.3 ± NA | 1.6 ± 0.85 | — |
| Change at Week 24 | — | — | 4.3 ± NA | 2.5 ± 1.48 | — |
| Change at Posttreatment Week 4 | 0.8 ± 1.46 | 1.8 ± 1.04 | 4.3 ± NA | 2.4 ± 1.27 | 2.1 ± 1.13 |
| Change at Posttreatment Week 12 | 1.2 ± 1.82 | 2.7 ± 0.97 | 5.0 ± NA | 3.4 ± 1.56 | 3.3 ± 1.18 |
| Change at Posttreatment Week 24 | 1.8 ± 2.31 | 4.1 ± 1.39 | 7.6 ± NA | 5.6 ± 0.85 | 4.7 ± 1.31 |
| kilograms | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 24 Weeks | 6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks |
|---|---|---|---|---|---|
| Change at Week 1 | 0.1 ± 1.00 | 0.3 ± 0.51 | -0.5 ± NA | 0.3 ± 1.34 | 0.1 ± 0.39 |
| Change at Week 2 | 0.3 ± 1.11 | 0.4 ± 0.54 | 0.0 ± NA | 0.3 ± 1.77 | 0.2 ± 0.44 |
| Change at Week 4 | 0.4 ± 1.44 | 0.5 ± 0.64 | 0.5 ± NA | 0.7 ± 1.91 | 0.3 ± 0.64 |
| Change at Week 8 | 0.5 ± 1.90 | 0.8 ± 0.84 | 1.3 ± NA | 0.6 ± 2.33 | 0.5 ± 0.66 |
| Change at Week 12 | 0.6 ± 2.32 | 1.1 ± 1.27 | 2.1 ± NA | 0.9 ± 2.90 | 0.6 ± 0.70 |
| Change at Week 16 | — | — | 1.6 ± NA | 1.2 ± 3.68 | — |
| Change at Week 20 | — | — | 2.2 ± NA | 1.8 ± 3.96 | — |
| Change at Week 24 | — | — | 3.1 ± NA | 2.4 ± 3.68 | — |
| Change at Posttreatment Week 4 | 0.9 ± 2.70 | 1.4 ± 1.48 | 1.8 ± NA | 2.2 ± 3.68 | 1.1 ± 1.09 |
| Change at Posttreatment Week 12 | 1.6 ± 3.48 | 2.1 ± 1.87 | 3.1 ± NA | 3.7 ± 2.90 | 1.2 ± 0.93 |
| Change at Posttreatment Week 24 | 3.2 ± 4.38 | 3.5 ± 2.75 | 4.5 ± NA | 5.7 ± 1.41 | 2.0 ± 1.57 |
Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.
| Participants | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF±RBV 12 or 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks |
|---|---|---|---|
| End of Treatment — No Change | 35 | 52 | 10 |
| End of Treatment — Increase | 1 | 1 | 0 |
| End of Treatment — Decrease | 0 | 1 | 0 |
| Posttreatment Week 12 — No Change | 32 | 51 | 9 |
| Posttreatment Week 12 — Increase | 3 | 2 | 0 |
| Posttreatment Week 12 — Decrease | 0 | 1 | 0 |
| Posttreatment Week 24 — No Change | 28 | 48 | 9 |
| Posttreatment Week 24 — Increase | 7 | 4 | 1 |
| Posttreatment Week 24 — Decrease | 0 | 1 | 0 |
Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.
| Participants | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF±RBV 12 or 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks |
|---|---|---|---|
| End of Treatment — No Change | 34 | 52 | 10 |
| End of Treatment — Increase | 1 | 1 | 0 |
| End of Treatment — Decrease | 0 | 1 | 0 |
| Posttreatment Week 12 — No Change | 33 | 50 | 9 |
| Posttreatment Week 12 — Increase | 2 | 4 | 0 |
| Posttreatment Week 12 — Decrease | 0 | 0 | 0 |
| Posttreatment Week 24 — No Change | 29 | 47 | 10 |
| Posttreatment Week 24 — Increase | 6 | 6 | 0 |
| Posttreatment Week 24 — Decrease | 0 | 0 | 0 |
Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.
| Participants | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF±RBV 12 or 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks |
|---|---|---|---|
| End of Treatment — No Change | 52 | 34 | 21 |
| End of Treatment — Increase | 9 | 2 | 0 |
| End of Treatment — Decrease | 1 | 0 | 0 |
| Posttreatment Week 12 — No Change | 45 | 31 | 22 |
| Posttreatment Week 12 — Increase | 15 | 3 | 0 |
| Posttreatment Week 12 — Decrease | 0 | 0 | 0 |
| Posttreatment Week 24 — No Change | 40 | 27 | 22 |
| Posttreatment Week 24 — Increase | 21 | 8 | 0 |
| Posttreatment Week 24 — Decrease | 0 | 0 | 0 |
Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.
| Participants | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF±RBV 12 or 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks |
|---|---|---|---|
| End of Treatment — No Change | 53 | 31 | 21 |
| End of Treatment — Increase | 8 | 5 | 0 |
| End of Treatment — Decrease | 1 | 0 | 0 |
| Posttreatment Week 12 — No Change | 49 | 25 | 21 |
| Posttreatment Week 12 — Increase | 11 | 8 | 1 |
| Posttreatment Week 12 — Decrease | 0 | 1 | 0 |
| Posttreatment Week 24 — No Change | 43 | 21 | 21 |
| Posttreatment Week 24 — Increase | 18 | 14 | 1 |
| Posttreatment Week 24 — Decrease | 0 | 0 | 0 |
Participants who were able/unable to swallow placebo tablets were assessed. Participants 12 to \< 18 years old were first asked to perform the swallowability assessment using the 90/400 mg placebo tablet. If they were unable to swallow this, they were then asked to perform the swallowability assessment with 22.5/100 mg placebo tablets. Participants 6 to \< 12 years old were to be assessed with the 22.5/100 mg placebo tablets. However, 8 participants were mistakenly assessed using the 90/400 mg placebo tablet.
| percentage of participants | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF±RBV 12 or 24 Weeks |
|---|---|---|
| Able to Swallow 90/400 mg Placebo Tablet | 89.0 | 100.0 |
| Unable to Swallow 90/400 mg Placebo Tablet | 11.0 | 0 |
| Able to Swallow 22.5/100 mg Placebo Tablet | 72.7 | 98.8 |
| Unable to Swallow 22.5/100 mg Placebo Tablet | 27.3 | 1.2 |
Participants who were dosed with granules were asked if they tasted the study drug. If they tasted it, then they were asked to provide a number from 0 to 100 to rate the taste of the study drug, with higher scores indicating better taste. Data was then summarized as percentage of participants choosing the following palatability categories: 1) Did not taste the study drug, 2) Tasted drug with score \> 60 to 100, 3) Tasted drug with score 40 to 60, and 4) Tasted drug with score of 0 to \< 40.
| percentage of participants | 3 to < 6 Years Old - LDV/SOF 12 Weeks |
|---|---|
| Did not taste the study drug | 41.2 |
| Tasted drug with score > 60 to 100 | 17.6 |
| Tasted drug with score 40 to 60 | 11.8 |
| Tasted drug with score of 0 to < 40 | 29.4 |
Collected over Adverse Events (AEs): First dose date up to Week 12 or 24 (depending on group) plus 30 days (includes AEs occurring during the PK Lead-in Phase); All-Cause Mortality: Up to Posttreatment Week 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 12 to < 18 Years Old - LDV/SOF 12 Weeks | 0/100 (0%) | 0/100 (0%) | 62/100 (62%) |
| 6 to < 12 Years Old - LDV/SOF 12 Weeks | 0/89 (0%) | 1/89 (1.1%) | 54/89 (60.7%) |
| 6 to < 12 Years Old - LDV/SOF 24 Weeks | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| 6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| 3 to < 6 Years Old - LDV/SOF 12 Weeks | 0/34 (0%) | 0/34 (0%) | 22/34 (64.7%) |
| Event | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 24 Weeks | 6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks |
|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/100 | 1/89 | 0/1 | 0/2 | 0/34 |
| GastroenteritisInfections and infestations | 0/100 | 1/89 | 0/1 | 0/2 | 0/34 |
| Tooth abscessInfections and infestations | 0/100 | 1/89 | 0/1 | 0/2 | 0/34 |
| Event | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 24 Weeks | 6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks |
|---|---|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 10/100 | 11/89 | 1/1 | 1/2 | 7/34 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/100 | 2/89 | 1/1 | 0/2 | 2/34 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 6/100 | 5/89 | 1/1 | 0/2 | 2/34 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 2/100 | 3/89 | 1/1 | 0/2 | 6/34 |
| Ear painEar and labyrinth disorders | 0/100 | 2/89 | 0/1 | 1/2 | 0/34 |
| Mouth ulcerationGastrointestinal disorders | 0/100 | 2/89 | 0/1 | 1/2 | 1/34 |
| NauseaGastrointestinal disorders | 11/100 | 9/89 | 0/1 | 1/2 | 1/34 |
| VomitingGastrointestinal disorders | 12/100 | 12/89 | 0/1 | 1/2 | 8/34 |
| FatigueGeneral disorders | 13/100 | 13/89 | 0/1 | 1/2 | 2/34 |
| PyrexiaGeneral disorders | 2/100 | 15/89 | 0/1 | 1/2 | 7/34 |
Safety Analysis Set included all participants who were enrolled into the study and received at least 1 dose of study drug.
| Age, Continuous(years) | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 24 Weeks | 6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks | Total |
|---|---|---|---|---|---|---|
| Mean | 15 ± 1.7 | 9 ± 1.6 | 11 ± NA | 9 ± 2.8 | 4 ± 0.7 | 11 ± 4.1 |
| Sex: Female, Male(Participants) | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 24 Weeks | 6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks | Total |
|---|---|---|---|---|---|---|
| Female | 63 | 36 | 1 | 1 | 24 | 125 |
| Male | 37 | 53 | 0 | 1 | 10 | 101 |
| Race/Ethnicity, Customized(Participants) | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 24 Weeks | 6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks | Total |
|---|---|---|---|---|---|---|
| White | 91 | 70 | 1 | 2 | 27 | 191 |
| Black or African American | 7 | 7 | 0 | 0 | 1 | 15 |
| Other | 0 | 5 | 0 | 0 | 4 | 9 |
| Asian | 2 | 5 | 0 | 0 | 2 | 9 |
| Native Hawaiian or Pacific Islander | 0 | 2 | 0 | 0 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 24 Weeks | 6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 13 | 9 | 0 | 0 | 6 | 28 |
| Not Hispanic or Latino | 85 | 75 | 1 | 2 | 28 | 191 |
| Not Disclosed | 2 | 5 | 0 | 0 | 0 | 7 |
| Region of Enrollment(Participants) | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 24 Weeks | 6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks | Total |
|---|---|---|---|---|---|---|
| New Zealand | 0 | 4 | 0 | 0 | 0 | 4 |
| United States | 91 | 70 | 0 | 0 | 29 | 190 |
| United Kingdom | 1 | 9 | 0 | 2 | 3 | 15 |
| Australia | 8 | 6 | 1 | 0 | 2 | 17 |
| HCV Genotype(Participants) | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 24 Weeks | 6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks | Total |
|---|---|---|---|---|---|---|
| Genotype 1 | 100 | 87 | 1 | 0 | 33 | 221 |
| Genotype 3 | 0 | 0 | 0 | 2 | 0 | 2 |
| Genotype 4 | 0 | 2 | 0 | 0 | 1 | 3 |
| Cirrhosis Status(Participants) | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 24 Weeks | 6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks | Total |
|---|---|---|---|---|---|---|
| Yes | 1 | 1 | 1 | 0 | 0 | 3 |
| No | 43 | 33 | 0 | 2 | 14 | 92 |
| Unknown | 56 | 55 | 0 | 0 | 20 | 131 |
| IL28b Status(Participants) | 12 to < 18 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 12 Weeks | 6 to < 12 Years Old - LDV/SOF 24 Weeks | 6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks | 3 to < 6 Years Old - LDV/SOF 12 Weeks | Total |
|---|---|---|---|---|---|---|
| CC | 24 | 23 | 0 | 0 | 10 | 57 |
| CT | 53 | 53 | 0 | 2 | 16 | 124 |
| TT | 23 | 12 | 1 | 0 | 6 | 42 |
| Missing | 0 | 1 | 0 | 0 | 2 | 3 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Nov 2014 to primary completion in Jun 2018, 43 months.
Results were first posted in Apr 2019, 10 months after primary completion.
Of 48 industry-sponsored phase 2 interventional studies under Hepatitis C, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 26. This study's 43 months is above that.
Counting every sponsor, half of 61 studies reached it within 19 months; a quarter within 13 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ribavirin